Compass Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Compass Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($66.49M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($49.38M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($42.49M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($39.23M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($82.18M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($29.50M) | Mar 18, 2022 |
| FY2020 | Mar 31, 2020 | ($37.5K) | Jun 8, 2020 |
| FY2020 | Dec 31, 2019 | ($34.74M) | Mar 5, 2021 |
| FY2020 | Mar 31, 2019 | ($36.0K) | Jun 8, 2020 |
| FY2019 | Mar 31, 2018 | ($35.1K) | Jul 1, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($72.84M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($56.63M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($50.36M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($41.66M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($81.88M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($27.81M) | Mar 18, 2022 |
| FY2020 | Mar 31, 2020 | ($32.1K) | Jun 8, 2020 |
| FY2020 | Dec 31, 2019 | ($34.05M) | Mar 5, 2021 |
| FY2020 | Mar 31, 2019 | ($32.8K) | Jun 8, 2020 |
| FY2019 | Mar 31, 2018 | ($35.0K) | Jul 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.97M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $42.34M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $38.12M | Feb 27, 2025 |
| FY2020 | Dec 31, 2020 | $14.90M | Mar 5, 2021 |
| FY2020 | Dec 31, 2019 | $22.45M | Mar 5, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($49.14M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($44.86M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($40.62M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($34.13M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($19.67M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($26.80M) | Mar 18, 2022 |
| FY2020 | Mar 31, 2020 | ($32.1K) | Jun 8, 2020 |
| FY2020 | Dec 31, 2019 | ($31.74M) | Mar 5, 2021 |
| FY2020 | Mar 31, 2019 | ($32.8K) | Jun 8, 2020 |
| FY2019 | Mar 31, 2018 | ($35.0K) | Jul 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.0K | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $44.0K | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $30.0K | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $212.0K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.57M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $106.0K | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $466.0K | Mar 5, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $219.59M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $140.40M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $156.88M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $199.65M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $153.76M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $51.91M | Mar 18, 2022 |
| FY2020 | Mar 31, 2020 | $3.7K | Jun 8, 2020 |
| FY2020 | Dec 31, 2019 | $30.38M | Mar 5, 2021 |
| FY2020 | Mar 31, 2019 | $4.9K | Jun 8, 2020 |
| FY2019 | Mar 31, 2018 | $25 | Jul 1, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.80M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $15.17M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $8.34M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $18.01M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $13.68M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $11.97M | Mar 18, 2022 |
| FY2020 | Mar 31, 2020 | $111.8K | Jun 8, 2020 |
| FY2020 | Dec 31, 2019 | $19.11M | Mar 5, 2021 |
| FY2020 | Mar 31, 2019 | $75.5K | Jun 8, 2020 |
| FY2019 | Mar 31, 2018 | $34.6K | Jul 1, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.79M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $125.23M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $148.54M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $181.64M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $140.08M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | $39.95M | Mar 15, 2023 |
| FY2020 | Mar 31, 2020 | ($108.1K) | Jun 8, 2020 |
| FY2021 | Dec 31, 2019 | $11.27M | Mar 18, 2022 |
| FY2020 | Mar 31, 2019 | ($70.6K) | Jun 8, 2020 |
| FY2020 | Dec 31, 2018 | ($84.77M) | Mar 5, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($431.17M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($364.68M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($315.31M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($272.81M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($233.59M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($151.41M) | Mar 18, 2022 |
| FY2020 | Mar 31, 2020 | ($108.6K) | Jun 8, 2020 |
| FY2020 | Dec 31, 2019 | ($121.91M) | Mar 5, 2021 |
| FY2020 | Mar 31, 2019 | ($71.1K) | Jun 8, 2020 |
| FY2019 | Mar 31, 2018 | ($35.1K) | Jul 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.64M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $43.48M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $24.23M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $34.95M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $144.51M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $47.08M | Mar 18, 2022 |
| FY2020 | Mar 31, 2020 | $3.7K | Jun 8, 2020 |
| FY2020 | Dec 31, 2019 | $25.30M | Mar 5, 2021 |
| FY2020 | Mar 31, 2019 | $4.9K | Jun 8, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 15, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 178.32M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 137.82M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 127.67M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 126.30M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 100.83M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 51.22M | Mar 18, 2022 |
| FY2020 | Mar 31, 2020 | 5.00M | Jun 8, 2020 |
| FY2020 | Dec 31, 2019 | 7.03M | Mar 5, 2021 |
| FY2020 | Mar 31, 2019 | 5.00M | Jun 8, 2020 |
| FY2019 | Mar 31, 2018 | 5.00M | Jul 1, 2019 |